• Lanadelumab effective against hereditary angioedema attacks

    One year ago - By Healio

    Subcutaneous lanadelumab, a monoclonal antibody drug, for 26 weeks significantly reduces attack rates of hereditary angioedema, according to data published in JAMA.
    The results of the trial supported the FDA approval of lanadelumab for hereditary angioedema, a rare, potentially life-threatening disorder caused by genetic mutations associated with decreased levels of, or dysfunctional, C1 inhibitor protein.
    “Our study and the subsequent FDA approval of lanadelumab have given patients with hereditary angioedema an important, novel option for preventive treatment,”
    Read more ...